Skip to main content

Table 1 Characteristics of PRL-induced carcinomas by histotype

From: Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer

  Glandular Solid Papillary Adenosquamous Carcinosarcoma
N 10 3 10 3 4
ERα1 10.0 ± 3.6 a 4.4 ± 2.9 b 21.1 ± 8.1 32.2 ± 10.2 a,b 8.2 ± 3.0
PR1 1.5 ± 1.0 0.3 ± 0.2 13.8 ± 6.3 2.4 ± 1.4 0
pStat51 49.0 ± 8.13a,b 66.6 ± 12.2 c,d,e 29.4 ± 18.7 c 23.9 ± 5.25 a,d 5.7 ± 1.9 b,e
c-Fos1 18.3 ± 2.8 a 15.0 ± 2.5b,c 17.6 ± 3.7 d 30.5 ± 4.4 a,b 25.2 ± 3.2 c,d
S phase1 15.6 ± 1.7 15.0 ± 2.5 18.0 ± 2.0 14.7 ± 1.3 15.5 ± 2.2
Apoptotic1 2.1 ± 0.3 3.6 ± 1.1 2.2 ± 0.3 1.9 ± 0.4 1.1 ± 0.2
pERK1/22 70% strong, 10% weak stromal; 30% epithelial 100% strong stromal 90% strong stromal; 10% epithelial 100% strong stromal 100% strong stromal & epithelial
pAKT2 50% epithelial; 20% stromal; 30% negative 67% epithelial; 33% negative 70% epithelial; 10% stromal; 20% negative 33% epithelial & stromal; 67% negative 75% epithelial; 25% negative
  1. 1% tumor epithelial cells that are positive, mean ± s.e.m (see Materials and methods). Same lower case letters indicate significant differences between histotypes (P < 0.05; Students t-test).
  2. 2% of tumors of each histotype that displayed strong staining in different locations (stroma, epithelium, or both) as indicated.
  3. ERα, estrogen receptor alpha; ERK, extracellular signal regulated kinase; PR, progesterone receptor; PRL, prolactin; Stat5, signal transducer and activator of transcription 5.